100% virological response and adherence in HCV genotype 1 liver cirrhosis treated with 3D regimen in a Romanian real-life cohort
AASLD LiverLearning®, Liliana Simona Gheorghe, 144896
Symptom Clusters Generated using Factorial Analysis of PROMIS tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis
AASLD LiverLearning®, Jasmohan S. Bajaj, 144653
Lack of compliance to hepatocellular carcinoma (HCC) screening guidelines in hepatitis B (HBV) or C (HCV) virus co-infected HIV patients with cirrhosis
AASLD LiverLearning®, Sophie Willemse, 144654
The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort
AASLD LiverLearning®, Eli Zuckerman, 144910
Real-Setting Treatment Data In People Who Inject Drugs Treated With Sofosbuvir-Based Regimens In Ukraine
AASLD LiverLearning®, Sergii Filippovych, 144655
Failure with DDA regimens in a high volume treatment center under real life conditions
AASLD LiverLearning®, Jorg Petersen, 144911
Sustained virologic response (SVR) in patients taking ledipasvir-sofosbuvir (LDV/SOF) and a proton pump inhibitor (PPI) in the treatment of chronic hepatitis C virus (HCV)
AASLD LiverLearning®, Jordan Mangum, 144912
Early hepatitis B surface antigen seroclearance after commencement of antiviral treatment in patients with de novo HBV reactivation
AASLD LiverLearning®, Haelim Lee, 144668
The role of IL-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection
AASLD LiverLearning®, Lung Yi Mak, 144669
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma
AASLD LiverLearning®, Giovanni Gaeta, 144670
Early Fluid Resuscitation in Cirrhotic Patients Diagnosed with Severe Sepsis is Associated with Decreased In-Hospital Mortality
AASLD LiverLearning®, James Crismale, 144926
Incidence, Determinants, and Outcomes of Pregnancy-Associated Hepatitis B Flares: A Regional Hospital-Based Cohort Study
AASLD LiverLearning®, Tatyana Kushner, 144671
Dengue fever in cirrhosis patients can lead to acute hepatic decompensation & increased mortality
AASLD LiverLearning®, Anand Kulkarni, 144927
Trends in Hospitalization for a Population-Based Cohort with Cirrhosis and Multiple Chronic Conditions: time to change the definition of decompensated cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 144928
Combined use of AST to platelet ratio index and Fibrosis-4 score can risk stratify hepatocellular carcinoma risk in chronic hepatitis B patients with low level viremia
AASLD LiverLearning®, Ji Hyeon Lee, 144684
US Asian HBV Patients Have Liver Steatosis and Metabolic Syndrome at Lower BMI than non Asians
AASLD LiverLearning®, William Clarke, 144685
Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014
AASLD LiverLearning®, Reem Waziry, 144686
Opioid use is associated with all-cause and sepsis-related death among patients with cirrhosis
AASLD LiverLearning®, Steven Scaglione, 144942
STAT4 rs7574865 polymorphism does not predict HBsAg loss in IFN treated genotype D HBeAg-negative patients with chronic Hepatitis B
AASLD LiverLearning®, Pietro Lampertico, 144687
The combined of Urine Neutrophil Gelatinase-associated Lipocalin and the CLIF-SOFA score in prediction of mortality of patients with acute-on-chronic liver failure
AASLD LiverLearning®, Tongluk Teerasarntipan, 144943
Thrombocytopenia is frequent finding in cirrhotic patients treated with piperacillin-tazobactan and is associated with increased morbidity and mortality
AASLD LiverLearning®, Gustavo Pereira, 144944
Dynamic changes of liver stiffness predict histological reverse of liver fibrosis in chronic hepatitis B patients treated with entecavir
AASLD LiverLearning®, Yuanyuan Kong, 144700
Prediction of hepatitis B virus-related liver cancer incidence and recurrence after anticancer therapy by hybrid evaluation of serum WFA(+)-M2BP and hepatitis B core-related antigen
AASLD LiverLearning®, Kazunori Kawaguchi, 144701
IL-22 Gene Haplotype Polymorphisms Are Associated with the Risk of Liver Cirrhosis in Patients with Hepatitis B Virus
AASLD LiverLearning®, Yanhang Gao, 144702
Fatty acid-binding proteins (FABPs) levels are increased in decompensated cirrhosis and associated with poor outcomes
AASLD LiverLearning®, Isabel Graupera, 144958
The SNP of HLA-DQ is associated with HCC in chronic HBV infection
AASLD LiverLearning®, Kentaro Yoshioka, 144703
Can Renalase Disfunction Influence Adrenergic Activation in Liver Cirrhosis?
AASLD LiverLearning®, Giovanni Sansoe', 144959
Adaptive Bayesian Analysis Personal Reference Ranges of Serum Creatinine and Urea for the Prediction of Acute Kidney Injury in Cirrhosis.
AASLD LiverLearning®, Kavish Patidar, 144960
Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA
AASLD LiverLearning®, Jens Verheyen, 144717
Serum microRNA-122 as well as WFA(+)-M2BP is a good predictor of liver fibrosis in chronic hepatitis B infection
AASLD LiverLearning®, Masato Nakamura, 144718
Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis.
AASLD LiverLearning®, Troels Busk, 144974
Clinical outcomes after spontaneous and nucleos(t)ide analogues (NUCs)-treated hepatitis B surface antigen(HBsAg) seroclearance in chronic HBV infection are favourable
AASLD LiverLearning®, Xiang-Yong Li, 144719
Deoxycholylglycine (DCG), a Conjugated Secondary Bile Acid (BA), Reduces Myogenic Tone by reducing Ca2+ Sensitivity via Rho kinase pathway
AASLD LiverLearning®, Sandeep Khurana, 144975
Engaging Chronic Hepatitis B at-risk populations into care: A peer-education intervention
AASLD LiverLearning®, Paul O`Neill, 144720
Cystatin C is better than creatinine for predicting prognosis in cirrhotic patients with sarcopenia
AASLD LiverLearning®, Hanah Lee, 144976
Switching to Tenofovir versus Continuing Entecavir in Chronic Hepatitis B Patients with Partial Virologic Response during Entecavir Therapy: STEEP Study
AASLD LiverLearning®, Hyung Joon Yim, 144733
Predictive role of serum HBsAg and HBcrAg levels in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon-based therapy
AASLD LiverLearning®, Pisit Tangkijvanich, 144734
Circulating microparticles carry apoptosis markers CK-18 and caspase-3/7 which are reduced by treatment with Emricasan in subjects with chronic liver diseases
AASLD LiverLearning®, Akiko Eguchi, 144990
No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients with Chronic Hepatitis B
AASLD LiverLearning®, Henry LY Chan, 144735
Emricasan (IDN-6556) Orally for 6 Months in Patients with Non-alcoholic Steatohepatitis (NASH) Cirrhosis Decreases the Progression of MELD score and Improves Liver Function
AASLD LiverLearning®, Catherine Frenette, 144991
Improved Renal Laboratory Parameters In CHB Patients Treated With TAF Compared With Tenofovir Disoproxil Fumarate (TDF)
AASLD LiverLearning®, Kaushik Agarwal, 144736
Aquaretic effects of α2A adrenergic receptor agonists (sympatholytic agents) vs. vasopressin V2 receptor antagonists in Experimental Ascitic Cirrhosis.
AASLD LiverLearning®, Giovanni Sansoe', 144992
Correlation of early biochemical and virologic responses during oral antiviral therapy for chronic hepatitis B
AASLD LiverLearning®, Maurizia Rossana Brunetto, 144749
Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients
AASLD LiverLearning®, Patrick Marcellin, 144750
HBV genotype is associated with early (week 12) virologic response during TDF or TAF therapy in patients with chronic hepatitis B
AASLD LiverLearning®, Subrat Acharya, 144751
4-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patient
AASLD LiverLearning®, Vincent Wong, 144752
A randomized trial evaluating the antiviral efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant chronic hepatitis B patients with undetectable hepatitis B virus DNA
AASLD LiverLearning®, JANG BYOUNG KUK, 144765
A real-world experience in baseline predictors of virological response to Peginterferon Alfa-2a in patients with HBeAg-negative chronic hepatitis B
AASLD LiverLearning®, Yi-Cheng Chen, 144766
The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis
AASLD LiverLearning®, Cihan Yurdaydin, 144767
Durability of 3-year consolidation therapy following virologic response in chronic hepatitis B patients treated with nuclios(t)ide analogues
AASLD LiverLearning®, Kwan Sik Lee, 144768
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemo-embolization
AASLD LiverLearning®, Sun Hong Yoo, 144782
Comparison of Renal safety of Tenofovir (TDF) and Entecavir (ETV) in Patients with Chronic Hepatitis B (CHB): A Systematic Review with Meta-Analysis
AASLD LiverLearning®, Hyo Young Lee, 144783
Serum HBsAg kinetics in relation to hepatitis flare during first 6 months of direct antiviral therapy
AASLD LiverLearning®, Wen-Juei Jeng, 144784
In vitro and in vivo anti-HBV activities of the new cyclophilin inhibitor STG-175
AASLD LiverLearning®, Philippe Gallay, 144785
Prevalence and Predictors of Fragility Fracture in Corticosteroid-treated Patients with Autoimmune Hepatitis (AIH)
AASLD LiverLearning®, Laura Harrison, 144541
Mycophenolate Mofetil in Autoimmune Hepatitis Patients not Responsive or Intolerant to Standard Therapy: the Australian TAPESTRY study
AASLD LiverLearning®, Alessia Gazzola, 144542
Analysis of the incidence of primary hepatocellular carcinoma in Japanese patients with hepatitis B virus infection stratified by primary liver cancer risk score at the start of Entecavir therapy
AASLD LiverLearning®, Yoshiyasu Karino, 144798
Understanding the importance of pro- and anti-inflammatory cytokines in autoimmune hepatitis
AASLD LiverLearning®, Jessica Dyson, 144543
Treatment efficacy of switching to tenofovir strategy over continued entecavir therapy in chronic hepatitis B patients with partial virologic response to entecavir
AASLD LiverLearning®, Jun Seop Lee, 144799
Evolution and Predictive Role of Basal Core Promoter and Precore Mutants in Genotype B or C Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Undergoing Peginterferon Therapy
AASLD LiverLearning®, Cheng Yuan Peng, 144800
Impact of age in renal safety of medium-term treatment with Entecavir and Tenofovir in real-life in a real-world cohort: Analysis of the Spanish national chronic hepatitis B register (CIBERHEP)
AASLD LiverLearning®, David Tabernero, 144801
IL-4 and IL-13 regulate liver fibrosis through M2 macrophages, but not Th2 T cells or hepatocytes
AASLD LiverLearning®, Shih-yen Weng, 144557
Inhibition of the substance P/neurokinin-1 receptor (NK-1R) axis decreases liver fibrosis in the Mdr2-/- mouse model of primary sclerosing cholangitis (PSC) through changes in senescence in cholangiocytes and hepatic stellate cells.
AASLD LiverLearning®, Guo-Ying Wang, 144558
Efficacy and safety of ombitasvir/ritonavir/paritaprevir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
AASLD LiverLearning®, Taeang Arai, 144814
Role of Incomplete Stem Cell Maturation in Hepatic Fibrosis
AASLD LiverLearning®, Ana Maretti-Mira, 144559
Treatment of chronic HCV Infection with direct antiviral agents (DAA) results in rapid regression of transient elastography (Fibroscan®) and validated fibrosis markers FIB-4 and APRI
AASLD LiverLearning®, Jacqueline Bachofner, 144815
Favorable efficacy of combination therapy with direct-acting antivirals to elderly aged 70 and older with HCV genotype 1
AASLD LiverLearning®, Norio Akuta, 144816
Daclatasvir plus Asunaprevir for Chronic Hepatitis C Virus Genotype 1b Infection; Real Life Data in Korea
AASLD LiverLearning®, Yang Jae Yoo, 144817
Mice with genetic deletion of ecto-nucleoside triphosphate diphosphohydrolase 3 (NTPDase3) are protected from development of both biliary and parenchymal-type liver fibrosis
AASLD LiverLearning®, Linda Feldbrugge, 144573
Systems biology approach to identify processes and early markers for fibrosis in metabolically-induced NASH in mice
AASLD LiverLearning®, Arianne van Koppen, 144574
Low hepatocelluar carcinoma (HCC) risk in HCV infected patients with liver cirrhosis or bridging fibrosis treated with different SOF-based DAA regimens: a single centre experience with a mean follow up of 12 months
AASLD LiverLearning®, Alessandra Mangia, 144830
Hyaluronan synthase-2-mediated hyaluronan overproduction in hepatic stellate cells contributes to liver fibrosis
AASLD LiverLearning®, Yoon Mee Yang, 144575
Interferon, Ribavirin or Direct Antiviral Agent-Based Regimens for Treatment of Hepatitis C Among Patient with Porphyria Cutanea Tarda
AASLD LiverLearning®, Krishna Venkata, 144831
High Effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection in Elderly Patients in a National Healthcare System
AASLD LiverLearning®, George Ioannou, 144832
Efficacy and safety of sofosbuvir-based therapies for cirrhotic and/or elder patients with hepatitis C virus in Japan
AASLD LiverLearning®, Akihiro Tamori, 144833
Th2-polarization of CD4+ T-cells is locally induced and drives liver fibrogenesis
AASLD LiverLearning®, Johanna Reissing, 144589
PlGF silencing ameliorates hepatic angiogenesis in mice with liver fibrosis induced by carbon tetrachloride
AASLD LiverLearning®, Chuantao Tu, 144590
Uptake of HCV Therapy in HIV/HCV Coinfected Patients across Europe in the Era of Direct-Acting Antivirals
AASLD LiverLearning®, Lars Peters, 144846
Functional analysis of a novel regeneration factor, Opioid growth factor receptor-like 1, that regulates both hepatic development and regeneration of injured/fibrotic liver
AASLD LiverLearning®, Takayo Yanagawa, 144591
Protease inhibitor and non-structural protein 5A inhibitor regimen can improve the health-related quality of life (HRQOL) in Japanese patients with genotype 1b hepatitis C virus
AASLD LiverLearning®, ikeda hiroki, 144847
LNCRNA H19 Is Increased In Hepatocellular Carcinoma With Underlying Hcv-Related Cirrhosis
AASLD LiverLearning®, Marta García-Valdecasas, 144848
The utilization of 8 weeks of sofosbuvir/ledipasvir single-tablet direct-acting antiviral regimen amongst the population indicated for the treatment in the United States
AASLD LiverLearning®, Sabina Heinz, 144849
Spleen stiffness is superior to liver stiffness for predicting esophageal varices in chronic liver disease: a meta-analysis
AASLD LiverLearning®, Xiaowen Ma, 144605
Psoas Muscle Density Improves Survival Predictability Following TIPS
AASLD LiverLearning®, Mohamed Shoreibah, 144606
Efficacy and safety of the currently recommended regimens with direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, George Papatheodoridis, 144862
Non-Invasive Prediction of Esophageal Varices After Antiviral Treatment: Analysis of a Long Term Follow-Up of 1605 Cases of Chronic Hepatitis C
AASLD LiverLearning®, Ragesh Babu Thandassery, 144607
Comorbidities, Co-medication and Potential Drug to Drug Interactions in Chronic Hepatitis C Patients (CHC): Implications for Adequate HCV Treatment Selection - Data from a large transversal study in Germany and France
AASLD LiverLearning®, Stefan Christensen, 144863
Maximizing access to HCV treatment with direct-acting antiviral agents for uninsured patients in the United States.
AASLD LiverLearning®, Andres Carrion, 144864
Exposure to sofosbuvir and daclatasvir is unchanged in liver transplant patients on cyclosporine or tacrolimus based immunosuppression
AASLD LiverLearning®, Lauriane Goldwirt, 144865
Impact of hepatitis C virus reflex testing on the hepatitis C care continuum among baby boomers in a urban health system
AASLD LiverLearning®, Aparna Goel, 144621
The association between alanine aminotransferase and renal function in the Japan population: the Yamagata (Takahata) study.
AASLD LiverLearning®, Hiroaki Haga, 144622
Safety and efficacy of Interferon-free antiviral treatment in Hepatitis C patients with MELD score 20 and over
AASLD LiverLearning®, Carmen Vinaixa, 144878
Randomized Controlled Trial of Outreach Strategies to improve Hepatocellular Carcinoma Screening Rates
AASLD LiverLearning®, Amit Singal, 144623
Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER study
AASLD LiverLearning®, Robert Flisiak, 144879
OMV/PTV/RTV +/- RBV in Genotype 4, Hard-To-Treat cohorts: real Life Data From Qatar
AASLD LiverLearning®, Moutaz Derbala, 144880
Improving Age-Based Hepatitis C Screening at a Veterans Affairs Primary Care Clinic
AASLD LiverLearning®, Jessica Rubin, 144637
Post-Discharge Mortality in a National Cohort of Veterans Affairs Patients with Cirrhosis
AASLD LiverLearning®, Jejo Koola, 144638
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials
AASLD LiverLearning®, Stefan Mauss, 144894
Impact of chronic diseases on the natural history of a Population-Based Cohort with Chronic Liver Disease: all cirrhotics are not equal
AASLD LiverLearning®, Sumeet Asrani, 144639
Sofosbuvir/Ledipasvir without Ribavirin is effective in the treatment of recurrent hepatitis C infection post liver transplant
AASLD LiverLearning®, Mohamed Shoreibah, 144895